Baseline demographic and clinical characteristics of B-ALL and LBCL
| Baseline demographic and clinical characteristics of B-ALL and LBCL cohorts . | ||||
|---|---|---|---|---|
| Characteristics . | NCI B-ALL . | Rejeski LBCL 2021 . | ||
| (n = 156) . | (n = 258) . | |||
| Age, median (range), y | 16 (4-39) | 63 (19-83) | ||
| Male sex, no. (%) | 108 (69) | 101 (56) (total n = 179) | ||
| No. of prior lines of therapy, median (range) | 5 (1-14) | 3 (2-11) | ||
| Previous autologous HSCT, no. (%) | 0 | 69 (27) | ||
| Previous allogeneic HSCT, no. (%) | 88 (56) | Not reported | ||
| % Baseline bone marrow disease, median (IQR) | 27.1 (1-81) | Not reported | ||
| Complete response, no. (%) | 114 (73) | Not reported | ||
| Severe CRS (≥grade 3), no. (%) | 29 (19) | Not reported | ||
| CAR product, no. (%) | ||||
| CD19 target containing constructs | CD19-22 bicistronic | 4 (3) | tisagenlecleucel | 88 (34) |
| CD19-22 bivalent | 29 (19) | axicabtagene autoleucel | 170 (66) | |
| CD19/28z | 49 (31) | |||
| CD22 targeted only | CD22/41BB | 74 (47) | ||
| Complete blood cell count, median | P value | |||
| ANC, cells per μL (95% CI) | 1370 | 2540 | P < .0001 | |
| (1020-1760) | (2310-2730) | |||
| Platelet count, ×103/μL (95% CI) | 124 | 164 | P = .0002 | |
| (92-141) | (152-178) | |||
| Hemoglobin, g/dL (95% CI) | 10.4 | 10.1 | P = .013 | |
| (10-10.9) | (9.7-10.4) | |||
| Markers of tumor burden and inflammation, median | ||||
| Lactate dehydrogenase, U/L (95% CI) | 221 (n = 155) | 276 | P < .0001 | |
| (207-235) | (260-302) | |||
| C-reactive protein, mg/dL (95% CI) | 0.42 (n = 142) | 1.02 | P = .0004 | |
| (0.24-0.68) | (0.80-1.40) | |||
| Ferritin, ng/mL (95% CI) | 1421 (n = 65) | 501 | P < .0001 | |
| (1011-1917) | (378-647) | |||
| Baseline demographic and clinical characteristics of B-ALL and LBCL cohorts . | ||||
|---|---|---|---|---|
| Characteristics . | NCI B-ALL . | Rejeski LBCL 2021 . | ||
| (n = 156) . | (n = 258) . | |||
| Age, median (range), y | 16 (4-39) | 63 (19-83) | ||
| Male sex, no. (%) | 108 (69) | 101 (56) (total n = 179) | ||
| No. of prior lines of therapy, median (range) | 5 (1-14) | 3 (2-11) | ||
| Previous autologous HSCT, no. (%) | 0 | 69 (27) | ||
| Previous allogeneic HSCT, no. (%) | 88 (56) | Not reported | ||
| % Baseline bone marrow disease, median (IQR) | 27.1 (1-81) | Not reported | ||
| Complete response, no. (%) | 114 (73) | Not reported | ||
| Severe CRS (≥grade 3), no. (%) | 29 (19) | Not reported | ||
| CAR product, no. (%) | ||||
| CD19 target containing constructs | CD19-22 bicistronic | 4 (3) | tisagenlecleucel | 88 (34) |
| CD19-22 bivalent | 29 (19) | axicabtagene autoleucel | 170 (66) | |
| CD19/28z | 49 (31) | |||
| CD22 targeted only | CD22/41BB | 74 (47) | ||
| Complete blood cell count, median | P value | |||
| ANC, cells per μL (95% CI) | 1370 | 2540 | P < .0001 | |
| (1020-1760) | (2310-2730) | |||
| Platelet count, ×103/μL (95% CI) | 124 | 164 | P = .0002 | |
| (92-141) | (152-178) | |||
| Hemoglobin, g/dL (95% CI) | 10.4 | 10.1 | P = .013 | |
| (10-10.9) | (9.7-10.4) | |||
| Markers of tumor burden and inflammation, median | ||||
| Lactate dehydrogenase, U/L (95% CI) | 221 (n = 155) | 276 | P < .0001 | |
| (207-235) | (260-302) | |||
| C-reactive protein, mg/dL (95% CI) | 0.42 (n = 142) | 1.02 | P = .0004 | |
| (0.24-0.68) | (0.80-1.40) | |||
| Ferritin, ng/mL (95% CI) | 1421 (n = 65) | 501 | P < .0001 | |
| (1011-1917) | (378-647) | |||
P value by Mann-Whitney test.
CI, confidence interval; IQR, interquartile range.